iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update
The quarterly net loss widened despite higher revenue, while IBIO-600 completed single ascending dose testing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
iBio (NASDAQ: IBIO) reported higher revenue and a wider net loss for its fiscal first quarter ended September 30, 2026. Revenue rose to $1.075 million from $100,000 a year earlier, while net loss widened to $7.551 million from $5.720 million. Loss per share narrowed to $0.05 from $0.11. Cash, cash equivalents and debt investments totaled approximately $76.7 million.
iBio completed single ascending dose testing of IBIO-600; it anticipates interim data and the start of multiple ascending dose testing in the first quarter of 2027. In obese non-human primates at week eight, fat represented 93% of weight lost with IBIO-610 plus semaglutide versus 77% with semaglutide alone; lean mass represented 6% versus 22%. The company targets an IBIO-610 IND-equivalent filing, seeking permission for human testing, by year-end 2026 and first-in-human studies in the first half of 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointIBIO-600 single ascending dose testing completed dosing in its first-in-human Phase 1 trial.
- Moderate point. Forward-looking: it has not happened yet and may not happen.IBIO-600 interim single-dose data and multiple-dose testing are anticipated in the first quarter of 2027.
- Moderate point. Forward-looking: it has not happened yet and may not happen.IBIO-610 targets an IND-equivalent filing by year-end 2026 and first-in-human studies in the first half of 2027.
- Minor pointRevenue rose to $1.075 million from $100,000 in the year-earlier quarter.
- Minor pointIBIO-610 combination preclinical results: 93% fat loss versus 77% of weight lost with semaglutide alone at week eight.
5 minor points
- Minor pointIBIO-610 combination preclinical results: 6% lean-mass loss versus 22% of weight lost with semaglutide alone at week eight.
- Minor pointLoss per share narrowed to $0.05 from $0.11 in the year-earlier quarter.
- Minor pointInterest income increased to $787,000 from $265,000 in the year-earlier quarter.
- Minor pointInterest expense fell to zero from $34,000 in the year-earlier quarter.
- Minor pointTotal liabilities declined to $10.081 million at September 30, 2026, from $13.397 million at June 30, 2026.
Negative
- Moderate pointNet loss widened to $7.551 million from $5.720 million in the year-earlier quarter.
- Moderate pointCash and equivalents declined to $45.435 million from $56.395 million between June 30 and September 30, 2026.
- Moderate pointCommon shares outstanding increased to 64,307,256 from 55,698,561 between June 30 and September 30, 2026, diluting holders.
- Minor pointResearch and development expenses increased to $6.650 million from $3.550 million in the year-earlier quarter.
- Minor pointGeneral and administrative expenses increased to $2.763 million from $2.501 million in the year-earlier quarter.
3 minor points
- Minor pointOperating loss widened to $8.338 million from $5.951 million in the year-earlier quarter.
- Minor pointDebt investments declined to $31.219 million from $31.644 million between June 30 and September 30, 2026.
- Minor pointStockholders’ equity declined to $78.570 million from $85.713 million between June 30 and September 30, 2026.
News Explained
iBio reported 64,307,256 common shares issued and outstanding as of
Key Figures
- Fat share of weight lost
- 93% vs. 77%
- Week eight; IBIO-610 with semaglutide vs. semaglutide alone in NHPs
- Lean-mass share of weight lost
- 6% vs. 22%
- IBIO-610 with semaglutide vs. semaglutide alone in NHPs
- Revenue
- $1.075M vs. $0.100M
- Three months ended September 30, 2026 vs. 2025
- Net loss
- $7.551M vs. $5.720M
- Three months ended September 30, 2026 vs. 2025
- Cash, cash equivalents and debt securities
- $76.7M
- As of September 30, 2026
- IBIO-600 interim Phase 1 data
- First quarter of 2027
- Anticipated interim data from the single ascending dose study
- IBIO-610 first-in-human trials
- First half of 2027
- Company expects to initiate trials
Previous Earnings Reports
-
Earlier earnings update reported 31 of 32 participants dosed in IBIO-600 single-ascending-dose cohorts.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
single ascending dose medical
GLP-1 receptor agonists medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Presented additional preclinical data supporting IBIO-610’s potential to drive fat selective weight loss in combination with GLP-1 therapy
Completed dosing in the single ascending dose portion of the Phase 1 clinical trial of IBIO-600
Plans to participate in upcoming scientific and investor conferences
SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced its financial results for the first quarter of fiscal year 2027, ended September 30, 2026, and provided a corporate update on its progress.
“This was a quarter of focus and execution as we advanced our portfolio of long-acting antibody therapeutics designed to address important challenges in obesity care,” said Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio. “The data presented at EASD strengthen our conviction in IBIO-610’s potential to deliver high-quality weight loss and provide important preclinical validation as we advance toward an IND-equivalent filing by the end of 2026, with plans to initiate first-in-human studies in the first half of 2027. We also anticipate advancing IBIO-600 in the multiple ascending dose portion of the Phase 1 trial in the first quarter of 2027 and progressing our preclinical programs that aim to address the entire spectrum of cardiometabolic disease care. Together, this progress brings us closer to our broader goal of helping people living with obesity achieve high-quality weight loss and better long-term health.”
First Fiscal Quarter 2027 & Recent Corporate Updates
- Presented additional preclinical body composition data from a study of IBIO-610, iBio’s long-acting Activin E antibody, in obese non-human primates (NHPs) at the European Association for the Study of Diabetes (EASD) Annual Meeting on October 1st.
- At week eight, fat accounted for
93% of the weight lost by NHPs receiving IBIO-610 in combination with semaglutide, compared with77% for NHPs receiving semaglutide alone. Lean mass accounted for6% and22% of weight lost, respectively. - These preclinical findings further support the potential of IBIO-610 to improve body composition, both as a standalone therapy and in combination with GLP-1 receptor agonists.
- iBio expects to initiate first-in-human trials of IBIO-610 in the first half of 2027.
- At week eight, fat accounted for
- Completed dosing in the single ascending dose (SAD) portion of the first-in-human Phase 1 clinical trial of IBIO-600, iBio’s long-acting anti-myostatin antibody being developed to preserve muscle and improve body composition.
- iBio anticipates interim Phase 1 data of the SAD study in the first quarter of 2027.
- The multiple ascending dose portion of the Phase 1 clinical trial is anticipated to start in the first quarter of 2027.
- Plans to participate in upcoming scientific and investor conferences, including:
- Guggenheim Healthcare Innovation Conference: November 9-11, 2026
- ObesityWeek 2026: November 14-17, 2026
- Protein & Antibody Engineering (PEGS) Europe 2026: November 16-19, 2026
- Jefferies Global Healthcare Conference: November 16-19, 2026
- Piper Sandler 38th Annual Healthcare Conference: December 1-3, 2026
- Amylin-Based Therapeutics Summit: December 1-3, 2026
Financial Results
- Revenues for the three months ended September 30, 2026 were approximately
$1.1 million , an increase of$1.0 over the$0.1 million in revenue for the three months ended September 30, 2025. - Research and Development (“R&D”) expenses for the three months ended September 30, 2026 and 2025 were approximately
$6.7 million and$3.6 million , respectively, an increase of approximately$3.1 million or approximately87% . The increase in R&D expenses is primarily due to increased spending of approximately$2.6 million for consultants and outside services supporting our R&D efforts, including the IBIO-600 Phase 1 human clinical trial, NHP studies and CMC activities, and an increase of approximately$0.3 million in personnel costs as a result of advancing research activities for our IBIO-600, IBIO-610, and IBIO-800 programs and other preclinical pipeline assets. - General and Administrative expenses for the three months ended September 30, 2026 and September 30, 2025, were approximately
$2.8 million and$2.5 million , respectively, an increase of approximately$0.3 million or approximately10% . The increase is primarily attributable to an increase in personnel costs and legal fees. - iBio held cash and cash equivalents and investments in debt securities of approximately
$76.7 million as of September 30, 2026.
About iBio, Inc.
iBio (Nasdaq: IBIO) is a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat diseases. Combining advanced antibody engineering with AI-driven discovery, iBio is advancing a differentiated pipeline designed to deliver sustained therapeutic effects and address significant unmet medical needs. iBio’s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.
For more information, visit www.ibioinc.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. These statements include, among others, statements regarding IBIO-610’s potential to deliver high-quality weight loss and provide important preclinical validation; iBio advancing toward an IND-equivalent filing for IBIO-610 by the end of 2026, with plans to initiate first-in-human studies in the first half of 2027; advancing IBIO-600 in the multiple ascending dose portion of the Phase 1 trial in the first quarter of 2027 and progressing iBio’s preclinical programs that aim to address the entire spectrum of cardiometabolic disease care; iBio helping people living with obesity achieve high-quality weight loss and better long-term health; the potential that adding IBIO-610 to GLP-1 therapy may improve the quality of weight loss by increasing the proportion of weight lost from fat while preserving muscle; initiating first-in-human trials of IBIO-610 in the first half of 2027; anticipated interim Phase 1 data of the SAD study in the first quarter of 2027; the multiple ascending dose portion of the Phase 1 clinical trial for IBIO-600 anticipated to start in the first quarter of 2027; and iBio’s planned participation in upcoming conferences. These statements reflect iBio’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks associated with meeting anticipated timelines, including an IND-equivalent filing for IBIO-610 by the end of 2026, initiating first-in-human studies in the first half of 2027, advancing IBIO-600 in the multiple ascending dose portion of the Phase 1 trial in the first quarter of 2027, initiating first-in-human trials of IBIO-610 in the first half of 2027 and the multiple ascending dose portion of the Phase 1 clinical trial for IBIO-600 starting in the first quarter of 2027 clinical trial enrollment and execution, the possibility that preclinical findings will not be replicated in humans, product development and regulatory approval, and the other risks described in iBio’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended June 30, 2026, and subsequent filings.
Forward-looking statements speak only as of the date of this release. iBio undertakes no obligation to update them except as required by law.
Investor Contact
Matt Beck
astr partners
matthew.beck@astrpartners.com
(917) 415-1750
Media Contact
Jason Braco, Ph.D.
Valence Communications
jason@valencecomms.com
| iBio, Inc. and Subsidiaries | ||||||||
| Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||||||
| (Unaudited; in thousands, except per share amounts) | ||||||||
| Three Months Ended | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| Revenue | $ | 1,075 | $ | 100 | ||||
| Operating expenses: | ||||||||
| Research and development | 6,650 | 3,550 | ||||||
| General and administrative | 2,763 | 2,501 | ||||||
| Total operating expenses | 9,413 | 6,051 | ||||||
| Operating loss | (8,338 | ) | (5,951 | ) | ||||
| Other income (expense): | ||||||||
| Interest income | 787 | 265 | ||||||
| Interest expense | — | (34 | ) | |||||
| Total other income | 787 | 231 | ||||||
| Net loss before income taxes | (7,551 | ) | (5,720 | ) | ||||
| Income tax expense | — | — | ||||||
| Net loss | $ | (7,551 | ) | $ | (5,720 | ) | ||
| Comprehensive loss: | ||||||||
| Net loss | $ | (7,551 | ) | $ | (5,720 | ) | ||
| Other comprehensive loss - unrealized loss on debt securities | (78 | ) | (15 | ) | ||||
| Comprehensive loss | $ | (7,629 | ) | $ | (5,735 | ) | ||
| Loss per common share - basic and diluted | $ | (0.05 | ) | $ | (0.11 | ) | ||
| Weighted-average common shares outstanding - basic and diluted - see Note 16 | 151,574 | 52,981 | ||||||
| iBio, Inc. and Subsidiaries | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (In thousands, except share and per share amounts) | ||||||||
| September 30, | June 30, | |||||||
| 2026 | 2026 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 45,435 | $ | 56,395 | ||||
| Accounts receivable - trade, net of allowance for credit losses of | 125 | — | ||||||
| Investments in debt securities (adjusted cost | 31,219 | 31,644 | ||||||
| Promissory note receivable and accrued interest | 1,124 | 1,104 | ||||||
| Prepaid expenses and other current assets | 3,336 | 3,078 | ||||||
| Total Current Assets | 81,239 | 92,221 | ||||||
| Restricted cash | 228 | 228 | ||||||
| Operating lease right-of-use asset, net of accumulated amortization | 1,566 | 1,667 | ||||||
| Fixed assets, net of accumulated depreciation | 3,021 | 3,086 | ||||||
| Intangible assets, net of accumulated amortization | 2,570 | 1,825 | ||||||
| Prepaid expenses - noncurrent | — | 73 | ||||||
| Security deposits | 27 | 10 | ||||||
| Total Assets | $ | 88,651 | $ | 99,110 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 4,409 | $ | 4,423 | ||||
| Accrued expenses | 3,404 | 5,626 | ||||||
| Operating lease obligation - current portion | 561 | 546 | ||||||
| Contract liabilities | 200 | 1,150 | ||||||
| Total Current Liabilities | 8,574 | 11,745 | ||||||
| Operating lease obligation - net of current portion | 1,507 | 1,652 | ||||||
| Total Liabilities | 10,081 | 13,397 | ||||||
| Stockholders' Equity | ||||||||
| Preferred Stock - | — | — | ||||||
| Common Stock - | 64 | 56 | ||||||
| Additional paid-in capital | 451,448 | 450,970 | ||||||
| Accumulated other comprehensive loss | (123 | ) | (45 | ) | ||||
| Accumulated deficit | (372,819 | ) | (365,268 | ) | ||||
| Total Stockholders’ Equity | 78,570 | 85,713 | ||||||
| Total Liabilities and Stockholders' Equity | $ | 88,651 | $ | 99,110 | ||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were iBio’s fiscal first-quarter 2027 financial results?
iBio reported $1.075 million in revenue and a $7.551 million net loss for the three months ended September 30, 2026. In the year-earlier quarter, revenue was $100,000 and net loss was $5.720 million. Basic and diluted loss per share was $0.05, compared with $0.11.
When does iBio expect its next IBIO-600 clinical milestones?
iBio anticipates interim single ascending dose data in the first quarter of 2027 and expects the multiple ascending dose portion of its Phase 1 trial to start in that quarter. Dosing in the single ascending dose portion has been completed.
Why did iBio’s research and development expenses rise in fiscal Q1 2027?
iBio attributes the increase primarily to approximately $2.6 million more spending on consultants and outside services and approximately $0.3 million more in personnel costs. Outside services supported the IBIO-600 Phase 1 trial, non-human primate studies, and chemistry, manufacturing and controls activities.